Market Cap

As of August 23, 2010: $30,159,000.00

Stock Chart

Circadian - 30 Day Poll

Recent BLOGS About Circadian Add New

There are no blogs to display.

Latest Company News

Phosphagenics Appoints Three New Non-Executive Directors to Boost Its Commercial Transformation
PharmaLive - Aug 25, 2010
MELBOURNE, August 24, 2010- Stuart James – former CEO & Managing Director of Mayne Pharma Sandra Webb – Director of Ground Zero Pharmaceuticals Don Clarke – Partner Minter Ellison, Deputy Chair of ...
Circadian Technologies Managing Director tops-up shareholding
Proactive Investors Australia - Aug 25, 2010
Circadian Technologies (ASX: CIR) Managing Director Robert Klupacs acquired 50,000 ordinary shares in on market purchases on 24th August at $0.60 per share. The Company is a publisher and is not ...
Circadian Technologies advancing biological cancer treatments, trades under asset backing
Proactive Investors Australia - Aug 20, 2010
by Proactive Investors Despite a significant development program in advancing its cancer treatments, Circadian Technologies (ASX: CIR) maintained significant cash reserves and listed investments ...

Website

Videos related to Circadian

Company Profile

Cash reserves plus listed investments (at market value): on 30th June 2010 were $33.8 million

Possible events in next 12 months:

 - VEGFR3 Abs IMC-3C5 for cancer (licensee ImClone) – IND filing sometime 2010

 - CUP molecular diagnostic – Validation of test completed by Healthscope 2010 (a test for unkown primaries)

 - click here for more possible events...

Overview:
Circadian has moved from being a biotechnology investor and incubator to a developer of angiogenesis-based therapeutics for cancer and other serious diseases. More specifically developing antibody therapies with an anti-angiogenic approach.

The portfolio covering key targets (Vascular Endothelial Growth Factors C and D) for the treatment of diseases associated with angiogenesis has been accumulated in Circadian’s unlisted subsidiary, Vegenics Limited. On August 14, 2008, Circadian announced that it had completed its acquisition of the Ludwig Institute for Cancer Research Ltd’s (LICR) and Licentia Limited’s (Licentia) combined 33% interest in Vegenics. This increased Circadian’s interest in Vegenics Limited from 67% to 100%.

The Group retains interests in two listed investments. These are in Antisense Therapeutics Limited and a small investment in Optiscan Imaging Limited. The combined market value of these investments (including indirect interests) as at 30 June 2010 was $1,922,324.

Has licensing deals with the following comapnies:
 - ImClone Systems Inc (recently acquired by Eli Lilly & Co.
 - Healthscope Limited (ASX:HSP) developing cancer diagnostic test

People:
Of note the "Product Development Advisory Committee" has strong experience in international drug developmentand oncology.
 – Errol Malta (Chair): ex Amgen
 – George Morstyn: ex CMO Amgen
 – Russell Howard: CEO Nasdaq listed Maxygen
 – Ralph Smalling: ex Amgen Reg Affairs
 – Richard Morgan: ex Glaxo-Wellcome
 – Carlo Montagner: ex Aventis, Schering, Abraxis


Top 10 Sahreholders include institutional and professional investors:
 - Packer and Co Limited 17.1
 - Select Asset Management Ltd 8.1
 - Ludwig Institute for Cancer Research 5.7
 - Licentia Ltd 5.6
 - Leon Serry 4.6
 - HSBC Custody Nominees 2.7
 - Chemical Trustee Limited 2.3
 - Jagen Pty Ltd 2.2
 - JFF Steven Pty Ltd 1.8
 - Audivac Pty Ltd 1.7

Total 10 shareholders own 51.8%

Related comapnies or competition:
 - Bionomics, see 
         http://www.bioinvest.com.au/company/Bionomics


Terms & Rules

As per ASIC Regulatory Guide 162: All investment tips and comments appearing on this website (Poll results, BLOGS & discussion forums) are submitted by the general public who are not licensed financial advisors. None of the information on this website is financial or investment advice, you should seek independent financial or investment advice by a licensed financial or investment advisor before entering into any position of financial risk. Before using this website, you must agree to the BioInvesting.com.au Terms Of Use

Before using this Biomedical Investing website

OR